Abacus Global Management will miss its deadline for the quarter ended September 30, 2026, pending review of limited partner capital credits and related-party transactions. Earlier reports back to June 30, 2025 may need correction.
ABX · Abacus Global Management, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $6.53
- Open
- $7.04
- Day range
- $6.45–7.19
- 52-week closing range
- $5.62–12.00
- Average volume, 30 days
- 846K
- Short interest
- 4.8M · 5.0% of shares · 8.2 days
- Short volume, last session
- 63%
- Last earnings
- Nov 5, 2026
- Latest filing
- 10-Q · Aug 10
- Price history
- Sep 2020 to Nov 2026
Up next
Latest documents
Third-quarter adjusted net income reached $29.4 million, above $26 to $28 million guidance, as Abacus Global Management raised full-year 2026 adjusted net income guidance to $104.5 to $106.5 million from $100 to $106 million.
Abacus Global Management reported third-quarter revenue of $76.9 M, adjusted net income of $29.4 M and adjusted EPS of $0.29, raised full-year 2026 adjusted net income guidance to $104.5M to $106.5M, and approved a $0.22 dividend payable December 16, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Abacus reported record Q2 revenue of $73.0M (+30% YoY) and adjusted EPS of $0.28, beating its guidance, and raised its Q3 adjusted EPS outlook to $0.26–$0.28 while reiterating full-year guidance of $1.00–$1.05. Longevity fund inflows of $544.2M in 1H26 surpassed the $500M target, the company launched its first registered interval fund (ABXGX), and GAAP net income declined 63% YoY due to acquisition-related and growth expenses.
- + Record Q2 revenue of $73.0M, up 30% YoY, driven by Life Solutions growth of 38.3%.
- + Longevity funds raised $544.2M in 1H26, surpassing the $500M target and approaching the ~$604M raised in all of 2025.
- + Launched the ABX Longevity Growth and Income Fund (ABXGX), the first registered interval fund for the longevity asset class, opening access to individual investors.
- + Q3 guidance implies adjusted EPS up to 17% YoY at $0.26–$0.28, and management is targeting the top end of the reiterated full-year range.
- − Asset management revenue declined YoY, driven by ETF AUM declines from market conditions and outflows.
- − Full-year adjusted EPS guidance of $1.00–$1.05 was reiterated rather than raised, even after a Q2 beat and higher Q3 outlook.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Research
our published analysis of this companyEquibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Average management fee on ETF Funds | 0.45% | Three Months Ended June 30, 2026 filing | — |
| Average management fee on Longevity Funds | 1.05% | Three Months Ended June 30, 2026 filing | — |
| Holding period on existing policies (in days) | 153 | Three Months Ended June 30, 2026 filing | — |
| Holding period on sold policies (in days) | 230 | Three Months Ended June 30, 2026 filing | — |
| Number of external counter parties that purchased policies | 6 | Three Months Ended June 30, 2026 filing | — |
| Number of policy originations to subsidiaries eliminated in consolidation | 138 | Three Months Ended June 30, 2026 filing | — |
| Policies bought | 288 | Three Months Ended June 30, 2026 filing | — |
| Policies bought from related parties | 8 | Three Months Ended June 30, 2026 filing | — |
| Policies matured | 19 | Three Months Ended June 30, 2026 filing | — |
| Policies originated for external investors | 44 | Three Months Ended June 30, 2026 filing | — |
| Policies sold | 300 | Three Months Ended June 30, 2026 filing | — |
| Policies sold to related parties | 278 | Three Months Ended June 30, 2026 filing | — |
| Total lifetime realized gains from maturities, net of lifetime premiums paid | $19,268,981 | Three Months Ended June 30, 2026 filing | — |
| Total lifetime realized gains, net of lifetime premiums paid | $62,032,077 | Three Months Ended June 30, 2026 filing | — |
| Turnover ratio | 2% | Three Months Ended June 30, 2026 filing | — |
| Weighted average realized gain on policies sold | 25.2% | Three Months Ended June 30, 2026 filing | — |
| Adjusted Annualized ROE non-GAAP | 22% | Six Months Ended June 30, 2026 | — |
| Adjusted Annualized ROIC non-GAAP | 20% | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA non-GAAP | $72,596,972 | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA Margin non-GAAP | 54.8% | Six Months Ended June 30, 2026 | — |
| Adjusted EPS (Gross) non-GAAP | $0.28 | 2Q26 | — |
| Adjusted EPS - Basic non-GAAP | $0.41 | Six Months Ended June 30, 2026 | — |
| Adjusted EPS - Diluted non-GAAP | $0.4 | Six Months Ended June 30, 2026 | — |
| Adjusted Net Income non-GAAP | $39,497,137 | Six Months Ended June 30, 2026 | — |
| Adjusted net income (Gross) non-GAAP | 27.1M | 2Q26 | — |
| Annualized ROE non-GAAP | 25% | 2Q26 | — |
| Annualized ROIC non-GAAP | 23% | 2Q26 | — |
| Average realized gain | 25% | 2Q26 | — |
| Longevity funds capital inflows | 256.1M | 2Q26 | — |
| Longevity funds new capital raised | 544.2M | first half of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Insurance - Life — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABX
this stock
Abacus Global Management, Inc.
|
$638.58M | -23.6% | +110.2% | 24.2 | 5.0% |
|
CILJF
China Life Insurance Co Ltd
|
$77.85B | -20.2% | — | — | 0.0% |
|
MFC
Manulife Financial Corp
|
$69.73B | +16.3% | — | — | 0.8% |
|
AFL
Aflac Inc
|
$61.71B | +13.1% | -9.3% | 18.4 | 1.8% |
|
MET
Metlife Inc
|
$61.34B | +23.6% | +8.6% | 12.7 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 23
Abacus Global Management will miss its deadline for the quarter ended September 30, 2026, pending review of limited partner capital credits and related-party transactions. Earlier reports back to June 30, 2025 may need correction.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABX | -25.6% | -23.3% | -27.9% | -22.9% | -23.6% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -20.2% | -17.0% | -22.2% | -17.6% | -28.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.